HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

J&J’s Consumer Woes Finally Subside As Pharma Continues Strong

This article was originally published in The Pink Sheet Daily

Executive Summary

The multinational health care company reported significant growth in 2013 that largely was driven by its pharmaceutical division, but bolstered by the resurrection of its long-plagued consumer brands.

You may also be interested in...



J&J’s Solid Launches Lead Strong Pharma Segment Quarter

Johnson & Johnson’s pharma unit posted strong sales growth in immunology and infectious disease, while its burgeoning oncology business is growing substantially.

Long-Acting Atypical Antipsychotic Market Snapshot: A One-Company Market Begins To Diversify

Otsuka and Lundbeck’s newly approved long-acting antipsychotic Abilify Maintena enters a sub-sector of the anti-psychotic market dominated by Johnson & Johnson for the last decade, but the new competitor may be able to gain ground by helping to grow the patient population.

J&J On Product Reformulation: Consumer Demand Plays A Role

Johnson & Johnson’s Susan Nettesheim, the consumer group VP of toxicology and product stewardship, says the firm’s recent decision to reformulate its personal care products without or with reduced levels of formaldehyde-releaser preservatives boiled down to responding to what consumers want.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS139824

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel